Convergent R.N.R.

Company Overview

Snapshot

Founded in September 2010 by Ze'ev Harel, Dr. Aharon Bar-David, Avigail Keller, and Zeev Burshtein, Convergent R.N.R. operates with 11–50 employees. The company has raised $3.7M across two funding rounds. In June 2017, Convergent R.N.R. established an alliance with MD Anderson to further develop its radiation technology.

Business overview

Convergent R.N.R. (also known as MercyBeam) is a medical technology startup focused on developing a novel X-ray focusing technology for cancer treatment. Its patented MercyBeam technology utilizes a standard imaging X-ray source to create a converging beam into a treatment volume, aiming to enhance the accuracy and safety of radiotherapy by sparing healthy organs and cells. The system incorporates a lens that collects divergent X-rays and converges them toward tumor locations, while simultaneously removing low-energy photons that could harm the patient's skin. This approach increases the therapeutic dose at the tumor site and significantly reduces exposure to surrounding healthy tissues, enabling the use of lower-energy photon X-rays compared to traditional linear accelerators. The company operates within the Health Tech & Life Sciences sector, specifically targeting Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers and patients.

Strategic signal

In June 2017, Convergent R.N.R. announced a strategic alliance with MD Anderson to advance the development of its MercyBeam radiation technology. This collaboration signals significant validation for Convergent R.N.R.'s innovative approach to cancer treatment, leveraging the expertise of a leading cancer center to refine a technology designed to reduce side effects and improve patient outcomes. For investors, this partnership indicates a strong potential for clinical adoption and further technological advancement within the oncology market.

Company Intelligence Q&A

What is Convergent R.N.R.'s core technology?

Convergent R.N.R.'s core technology is MercyBeam, a patented X-ray focusing system designed to improve the accuracy and safety of radiotherapy for cancer treatment. It uses a lens to converge X-rays from a standard source onto tumors, minimizing damage to healthy tissue.

When was Convergent R.N.R. founded?

Convergent R.N.R. was founded in September 2010.

Which organization did Convergent R.N.R. partner with for technology development?

In June 2017, Convergent R.N.R. established an alliance with MD Anderson to further develop its radiation technology.

How much capital has Convergent R.N.R. raised?

Convergent R.N.R. has raised a total of $3.7M across two funding rounds.

What is the primary goal of the MercyBeam technology?

The primary goal of the MercyBeam technology is to make radiotherapy treatment more accurate and safe, sparing healthy organs and cells by delivering a concentrated therapeutic dose to the tumor while reducing exposure to surrounding tissues.